Should You Continue to Hold ILMN Stock in Your Portfolio?

{
  "signal_id": "5092bc8b-aa46-ae84-db7c-982313dd08ba",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-07-03T12:53:00+00:00",
  "company": {
    "name": "Illumina",
    "domain": "illumina.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/zacks:07e37f738094b:0-should-you-continue-to-hold-ilmn-stock-in-your-portfolio/",
    "title": "Should You Continue to Hold ILMN Stock in Your Portfolio? - TradingView",
    "excerpt": "Illumina Inc. ILMN is well-poised to grow in the coming quarters owing to its strategic execution against growing the core sequencing business, expanding multiomics and developing services, data and software capabilities. Ongoing momentum in clinical end markets is boosting sequencing consumables demand. Higher-than-expected NovaSeq X placements and continued transition to the platform further strengthen the outlook. Yet, China remains a drag on Illumina’s growth, while input-cost volatility can limit incremental margin upside over the next several quarters. Over the past year, this Zacks Rank #3 (Hold) stock has surged 87%, well ahead of the industry’s 23.8% growth and the S&P 500 composite’s rise of 22.8%. The renowned biotechnology company has a market capitalization of $27.82 billion. ILMN’s earnings yield of 2.8% is well ahead of the industry’s -14.9% yield. In the trailing four quarters, it surpassed estimates on all occasions, delivering an average surprise of 12.2%. Let’s delve deeper. Tailwinds Behind ILMN Stock Sharpened Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has continued to center its strategy on the core sequencing franchise while scaling into adjacent multiomics and data offerings. The company remains focused on returning to durable growth and higher profitability, aiming for high-single-digit revenue growth by 2027, along...",
    "summary": "Illumina raised its full-year 2026 revenue guidance to a range of $4.52-$4.62 billion.",
    "planning": true,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.9,
    "published_at": "2026-07-03T12:53:00Z",
    "article_sentence": "Management also raised full-year 2026 guidance, now expecting revenues in the range of $4.52-$4.62 billion and non-GAAP diluted EPS in the range of $5.15-$5.30, alongside a modest step-up in the non-GAAP operating margin outlook between 23.4% and 23.6%.",
    "amount_normalized": 4620000000
  }
}

curl https://signals.autobound.ai/v1/signals/5092bc8b-aa46-ae84-db7c-982313dd08ba \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"illumina.com","limit":20}'